Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TR
VanEck Healthcare TruSector ETF
TRUH
Volume
987
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TR
TRUH
TR
VanEck Healthcare TruSector ETF
TRUH
News
·
AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients
AUM
N/A
Volume
987
Yield
1.69%
Chart
Earnings
News
About
Dividends
Insider
Filings
AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients
AbbVie announced nine-year Phase 3 CLL14 trial data showing venetoclax plus obinutuzumab significantly improved progression-free survival (6.4 years vs 3.2 years) compared to chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia patients. The fixed-duration combination demonstrated median time to next treatment of 7.6 years with sustained safety and efficacy.
Benzinga · Jun 12, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
TR
TRUH
VanEck Healthcare TruSector ETF
Buy
Sell
Market
Limit
Soon
TRUH
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any TRUH yet.
Related Tickers
Earnings
Dividends
Last · Oct 1
Quarterly
Amount
$0.13
Yield
0.70%
Annual
$0.22